Quest Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a healthy return on capital (ROCE) of 43.6%
- Company has a good return on equity (ROE) track record: 3 Years ROE 37.0%
- Latest quarter profit grew 47.9% YoY, showing strong momentum
- Operating margins have improved to 15.4% from 11.0%
- Company comfortably covers its interest (21.6x coverage)
- Attractively priced for its growth - PEG of 0.2
CONS
- Operating cash flow has been negative in recent years
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.57x)
- Equity base is being diluted - shares outstanding up 1419.0%
- Total debt has risen sharply - up 495.1% year on year
- Working capital days have increased from 89 to 245 days
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| QUESTLAB | 84.70 | 9.24 | 138.80 | 0.00 | 2.87 | 47.94 | 32.41 | -30.23 | 26.87 | 12.77 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 15 | 27 | 15 | 46 | 23 | 26 | 31 | 32 | |
| 13 | 19 | 14 | 45 | 19 | 22 | 24 | 28 | |
| Operating Profit | 2 | 9 | 1 | 1 | 4 | 3 | 7 | 4 |
| OPM % | 11.67% | 32.15% | 4.51% | 2.45% | 16.47% | 13.23% | 22.57% | 12.77% |
| 0 | 1 | 0 | 3 | 2 | 1 | 1 | -1 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before Tax | 2 | 9 | 1 | 4 | 5 | 4 | 7 | 2 |
| Tax % | 11.38% | 32.44% | 0.00% | 47.14% | 14.91% | 0.00% | 40.82% | -16.67% |
| Net Profit | 1 | 6 | 1 | 2 | 4 | 4 | 4 | 3 |
| 0.90 | 3.70 | 0.47 | 1.18 | 2.50 | 2.45 | 2.46 | 1.74 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | 112 | |
| 29 | 53 | 54 | 67 | 88 | 94 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 18 |
| OPM % | 4.67% | 10.87% | 12.73% | 18.85% | 15.37% | 16.33% |
| 0 | 0 | 0 | 0 | 4 | 3 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before Tax | 1 | 6 | 7 | 14 | 19 | 18 |
| Tax % | 17.04% | 28.82% | 27.74% | 30.13% | 27.39% | 17.05% |
| Net Profit | 1 | 4 | 5 | 10 | 14 | 15 |
| EPS | 0.61 | 3.81 | 46.76 | 8.46 | 8.28 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 20%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 49%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -13%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 35%
- 3 Years:
- 37%
- Last Year:
- 25%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| 5 | 9 | 14 | 17 | 65 | |
| 3 | 3 | 4 | 5 | 30 | |
| Trade Payables | 8 | 17 | 25 | 21 | 6 |
| 2 | 5 | 3 | 6 | 4 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 |
| 6 | 7 | 10 | 10 | 12 | |
| 0 | 0 | 0 | 7 | 52 | |
| 1 | 1 | 11 | 16 | 21 | |
| 0 | 0 | 0 | 24 | 30 | |
| Cash & Bank | 0 | 2 | 0 | 0 | 0 |
| 11 | 25 | 26 | 3 | 6 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 4 | 6 | 3 | -23 | |
| Cash from Investing | -1 | -2 | -4 | -5 | -44 |
| Cash from Financing | 0 | -0 | 0 | 2 | 67 |
| -0 | 1 | 0 | 0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for QUESTLAB
Loading news…
AI Stock Analyst
Quest Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account